FDA approves Wegovy for cardiovascular disease

“Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight,”John Sharretts, the director of the diabetes and obesity division of the FDA’s Center for Drug Evaluation and Research.

Martin Holst Lange, executive vice president and head of development at Novo Nordisk, said in the press statement that the company is “very pleased” about Friday’s announcement. “This approval is an important milestone for people living with obesity and cardiovascular disease, as the SELECT data demonstrated that Wegovyhas the potential to prolong lives by addressing some of the leading causes of preventable deaths by reducing the risks of cardiovascular events,” Lange said.

According to the FDA, nearly 70% of adults in the U.S. are medically overweight or obese, conditions that increase the risk of premature death and a multitude of health problems.that Wegovy could prevent as many as 1.5 million heart attacks in the United States over the next 10 years.Heart disease cost the United States nearly $240 billion each year between 2018 and 2019, including medicine, healthcare services, and loss of productivity due to death.

“FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight,” Sharretts said.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves Wegovy to reduce heart attack and stroke riskBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

More teens are using weight loss drugs like Wegovy and OzempicMarina Kopf is an associate producer with the NBC News Health and Medical Unit.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

Novo Nordisk’s New Obesity Pill Beats Wegovy In Early TrialI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Source: Forbes - 🏆 394. / 53 Read more »

Novo Nordisk settles two lawsuits over copycat versions of Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

Novo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverageWegovy and its diabetes counterpart Ozempic sparked a weight loss industry gold rush over the past year for their ability to help patients shed pounds
Source: NBCNewYork - 🏆 270. / 63 Read more »